Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation

Cancer Research

Volumn 57, Issue 21, 1997, Pages 4765-4776

  Lee, Chyi Chia R ^a   Yamamoto, Shinji ^a   Wanibuchi, Hideki ^a   Wada, Seiji ^a   Sugimura, Kazunobu ^a   Kishimoto, Taketoshi ^a   Fukushima, Shoji ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLINE; MESSENGER RNA; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PROTEIN P53;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOGENESIS; CANCER STAGING; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; RAT; TUMOR SUPPRESSOR GENE;

ANIMALS; ASCORBIC ACID; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOGENS; CARCINOMA, TRANSITIONAL CELL; CELL NUCLEUS; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; HYPERPLASIA; MALE; NEOPLASM PROTEINS; PAPILLOMA; PRECANCEROUS CONDITIONS; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, INBRED F344; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0030731914     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Matsushime, H., Roussel, M. F., Ashmun, R. A., and Sherr, C. J. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell, 65: 701-713, 1991.
2. Motokura, T., Bloom, T., Kim, H. G., Juppner, H., Rudderman, J. V., Kronenberg, H. M., and Arnold, A. A novel cyclin encoded by a bcl 1-linked candidate oncogene. Nature (Lond.), 350: 512-515, 1991.
3. 1 events and regulation of cell proliferation. Science (Washington, DC), 246: 603-608, 1989.
4. Naitoh, H., Shibata, J., Kawaguchi, A., Kodama, M., and Hattori, T. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am. J. Pathol., 146: 1161-1169, 1995.
5. Zhang, S. Y., Caamano, J., Cooper, F., Guo, X., and Klein-Szanto, A. J. P. Immunohistochemistry of cyclin D1 in human breast cancer. Am. J. Clin. Pathol., 102: 695-698, 1994.
6. McIntosh, G. G., Anderson, J. J., Milton, I., Steward, M., Parr, A. H., Thomas, M. D., Henry, J. A., Angus, B., Lennard, T. W., and Horne, C. H. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene, 11: 885-891, 1995.
7. Nishida, N., Fukuda, Y., Komeda, T., Kita, R., Sando, T., Furukawa, M., Amenomori, M., Shibagaki, I., Nakao, K., Ikenaga, M., and Ishizaki, K. Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res., 54: 3107-3110, 1994.
8. Betticher, D. C., Heighway, J., Hasleton, P. S., Altermatt, H. J., Ryder, W. D., Cerny, T., and Thatcher, N. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br. J. Cancer. 73: 294-300, 1996.
9. Lee, C. C. R., Yamamoto, S., Morimura, K., Wanibuchi, H., Nishisaka, N., Ikemoto, S., Nakatani, T., Wada, S., Kishimoto, S., and Fukushima, S. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer (Phila.), 79: 780-789, 1997.
10. Motokura, T., and Arnold, A. Cyclin D1 and oncogenesis. Curr. Opin. Genet. Dev., 3: 5-10, 1993.
11. Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E., Tsujimoto, Y., Harris, N. L., and Arnold, A. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc. Natl. Acad. Sci. USA, 88: 9638-9642, 1991.
12. Wang, T. C. Cardiff, R. D., Zukerberg, L. R., Lees, E., Arnold, A., and Schmidt, E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 (PRAD-1) transgenic mice. Nature (Lond.), 369: 669-671, 1994.
13. Bianchi, A. B., Fischer, S. M., Robles, A. J., Rinchik, E. M., and Conti, C. J. Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene, 8: 1127-1133, 1993.
14. Said, T. K., and Medina, D. Cell cyclins and cyclin-dependent kinase activities in mouse mammary tumor development. Carcinogenesis (Lond.), 16: 823-830, 1995.
15. Wang, Q. S., Sabourin, C. L. K., Wang, H., and Stoner, G. D. Overexpression of cyclin D1 and cyclin E in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Carcinogenesis (Lond.), 17: 1583-1588, 1996.
16. Youssef, E. M., Hasuma, T., Morishima, Y., Takada, N., Osugi, H., Higashino, M., Otani, S., and Fukushima, S. Overexpression of cyclin D1 in rat esophageal carcinogenesis model. Jpn. J. Cancer Res., 88: 18-25, 1997.
17. Robles, A., and Conti, C. J. Early overexpression of cyclin D1 protein in mouse skin carcinogenesis. Carcinogenesis (Lond.), 16: 781-786, 1995.
18. Sgambato, A., Han, E. K. H., Zhang, Y. J., Moon, R. C., Santella, R. M., and Weinstein, I. B. Deregulated expression of cyclin D1 and other cell cycle-related genes in carcinogen-induced rat mammary tumors. Carcinogenesis (Lond.), 16: 2193-2198, 1995.
19. Fukushima, S., Imaida, K., Sakata, T., Okamura, T., Shibata, M., and Ito, N. Promoting effects of sodium L-ascorbate on two-stage urinary bladder carcinogenesis in rats. Cancer Res., 43: 4454-4457, 1983.
20. Ito, N., and Fukushima, S. Promotion of urinary bladder carcinogenesis in experimental animals. Exp. Pathol., 36: 1-15, 1989.
21. Fukushima, S., Murasaki, G., Hirose, M., Nakanishi, K., Hasegawa, R., and Ito, N. Histopathological analysis of preneoplastic changes during N-butyl-N-(4-hydroxybutyl)nitrosamine induced urinary bladder carcinogenesis in rats. Acta Pathol. Jpn., 32: 243-250, 1982.
22. Sugimura, K., Lee, C. C. R., Kim, T., Goto, T., Kasai, S., Harimoto, K., Yamagami, S., and Kishimoto, T. Production of hepatocyte growth factor is increased in chronic renal failure. Nephron, 75: 7-12, 1997.
23. Orita, M., Suzuki, Y., Sekiya, T., and Hayashi, K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5: 874-879, 1989.
24. Masui, T., Don, I., Takada, N., Ogawa, K., Shirai, T., and Fukushima, S. p53 mutations in early neoplastic lesions of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis (Lond.), 15: 2379-2381, 1994.
25. Lipponen, P. K., and Eskelinen, M. J. Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value. Br. J. Cancer, 66: 171-176, 1992.
26. Esrig, D., Spruck, C. H. III., Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S. C., Skinner, D. G., Jones, P. A., and Cote, R. J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol., 143: 1389-1397, 1993.
27. Fukushima, S., Tanaka, H., Asakawa, B., Kagawa, M., Yamamoto, A., and Shirai, T. Carcinogenicity of uracil, a nongenotoxic chemical, in rats and mice and its rationale. Cancer Res., 52: 1675-1680, 1992.
28. Ito, N., Hiasa, Y., Tamai, A., Okajima, E., and Kitamura, H. Histogenesis of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats. Gann, 60: 401-410, 1969.
29. Ito, N., Matayoshi, K., Arai, M., Yoshioka, Y., Kamamoto, Y., Makiura, S., and Sugihara, S. Effect of various factors on induction of urinary bladder tumors in animals by N-butyl-N-(4-hydroxybutyl)nitrosamine. Gann, 64: 151-159, 1973.
30. Asamoto, M., Mann, A. M., and Cohen, S. M. p53 mutation is infrequent and might not give a growth advantage in rat bladder carcinogenesis in vivo. Carcinogenesis (Lond.), 15: 455-458, 1994.
31. Spruck, C. H. III., Ohneseit, P. F., Gonzalez-Zulueta, M., Esrig, D., Miyao, N., Tsai, Y. C., Lerner, S. P., Schumutte, C., Yang, A. S., Cote, R., Dubeau, L., Nichols, P. W., Hermann, G. G., Steven, K., Horn, T., Skinner, D. G., and Jones, P. A. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54: 784-788, 1994.
32. Keyomarsi, K., O'Leary, N., Molnar, G., Lees, E., Fingert, H. J., and Pardee, A. B. Cyclin E. a potential prognostic marker for breast cancer. Cancer Res., 54: 380-385, 1994.
33. 1 cyclins and cyclin-dependent kinases during tumor progression of chemically induced mouse skin neoplasms. Mol. Carcinog., 18: 142-152, 1997.
34. Masui, T., Mann, A. M., Macatee, T. L., Okamura, T., Garland, E. M., Smith, R. A., and Cohen, S. M. Absence of ras oncogene activation in rat urinary bladder carcinomas induced by N-methyl-N-nitrosourea or N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis (Lond.), 13: 2281-2285, 1992.
35. Xiong, Y., Hannom, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
36. El-Deiry, W. S., Tokino, T, Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
37. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.), 369: 574-579, 1994.
38. Xiong, Y., Zhang, H., and Beach, D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell, 71: 505-514, 1992.
39. Xiong, Y., Zhang, H., and Beach, D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev., 7: 1572-1583, 1993.
40. Zhang, H., Hannon, G. J., and Beach, D. p21 containing cyclin kinases exist in both active and inactive states. Genes Dev., 8: 1750-1758, 1994.
41. Yang, Z-Y., Perkins, N. D., Ohno, T., Nabel, E. G., and Nabel, G. J. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat. Med., 1: 1053-1056, 1995.